{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:44:29Z","timestamp":1761518669999},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[1997,2,1]],"date-time":"1997-02-01T00:00:00Z","timestamp":854755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T00:00:00Z","timestamp":1577404800000},"content-version":"vor","delay-in-days":8364,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[1997,2]]},"DOI":"10.1023\/a:1008295427877","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T13:47:34Z","timestamp":1040564854000},"page":"155-162","source":"Crossref","is-referenced-by-count":66,"title":["Doubling epirubicin dose intensity (100 mg\/m2 versus 50 mg\/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer"],"prefix":"10.1016","volume":"8","author":[{"given":"G.","family":"Brufman","sequence":"first","affiliation":[]},{"given":"E.","family":"Colajori","sequence":"additional","affiliation":[]},{"given":"N.","family":"Ghilezan","sequence":"additional","affiliation":[]},{"given":"M.","family":"Lassus","sequence":"additional","affiliation":[]},{"given":"M.","family":"Martoni","sequence":"additional","affiliation":[]},{"given":"N.","family":"Perevodchikova","sequence":"additional","affiliation":[]},{"given":"C.","family":"Tosello","sequence":"additional","affiliation":[]},{"given":"D.","family":"Viaro","sequence":"additional","affiliation":[]},{"given":"C.","family":"Zielinski","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1023\/A:1008295427877_bb0005","first-page":"8","article-title":"Cancer statistics, 1995","volume":"45","author":"Wingo","year":"1995","journal-title":"CA"},{"key":"10.1023\/A:1008295427877_bb0010","series-title":"Harris JR, Hellman S, Henderson IC, Kinne DW (eds): Breast Diseases","article-title":"Principles in the management of metastatic disease","author":"Henderson","year":"1991"},{"key":"10.1023\/A:1008295427877_bb0015","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.1996.14.8.2197","article-title":"Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer","volume":"14","author":"Greenberg","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008295427877_bb0020","first-page":"1523","article-title":"Chemotherapy versus chemoimmunotherapy (CAF vs","volume":"5","author":"Aisner","year":"1987","journal-title":"CAFVP vs. CMF each \u00b1MER) for metastatic carcinoma of the breast: A CALGB study. J Clin Oncol"},{"key":"10.1023\/A:1008295427877_bb0025","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00000421-198406000-00007","article-title":"A comparison of intermittent v continuous and of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer","volume":"7","author":"Tormey","year":"1984","journal-title":"Am J Clin Oncol"},{"key":"10.1023\/A:1008295427877_bb0030","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/1097-0142(197805)41:5<1649::AID-CNCR2820410501>3.0.CO;2-J","article-title":"A randomised comparative trial of adriamycin vs methotrexate on combination drug therapy","volume":"41","author":"Bull","year":"1978","journal-title":"Cancer"},{"key":"10.1023\/A:1008295427877_bb0035","first-page":"932","article-title":"Comparison of CAF vs","volume":"3","author":"Cunnings","year":"1985","journal-title":"CMFP in metastatic breast cancer: analysis of prognostic factors. J Clin Oncol"},{"key":"10.1023\/A:1008295427877_bb0040","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF01803563","article-title":"A comparison of cyclophosphamide, adriamycin and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate and 5-fluorouracil, vincristine and prednisone (CMFVP) in patients with advanced breast cancer","volume":"3","author":"Smalley","year":"1983","journal-title":"Breast Cancer Res Treat"},{"key":"10.1023\/A:1008295427877_bb0045","first-page":"3","article-title":"Applications of dose intensity to the problems in chemotherapy of breast cancer and colorectal cancer","volume":"4","author":"Hryniuk","year":"1987","journal-title":"Semin Oncol"},{"key":"10.1023\/A:1008295427877_bb0050","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1200\/JCO.1988.6.6.976","article-title":"Phase III randomised study of fluorouracil, epirubicin and cyclophosphamide vs fluorouracil, doxorubicin and cyclophosphamide in advanced breast cancer: An Italian multricenter trial","volume":"6","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008295427877_bb0055","first-page":"261","article-title":"Phase II study of doxorubicin vs epirubicin in advanced breast cancer","volume":"70","author":"Brambilla","year":"1986","journal-title":"Cancer Treat Rep"},{"issue":"4","key":"10.1023\/A:1008295427877_bb0060","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1200\/JCO.1988.6.4.679","article-title":"A prospective randomised phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil and either doxorubicin or epirubicin","volume":"6","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008295427877_bb0065","series-title":"A phase II study. Preliminary results. Proc Am Soc Oncol","first-page":"116","article-title":"Epirubicin as first-line chemotherapy in disseminated breast carcinoma","author":"Carmo Pereira","year":"1989"},{"key":"10.1023\/A:1008295427877_bb0070","series-title":"Proc Am Soc Oncol","first-page":"87","article-title":"Phase I study of epirubicin in metastatic breast cancer","author":"Blackstein","year":"1988"},{"key":"10.1023\/A:1008295427877_bb0075","first-page":"85","article-title":"High dose epirubicin as initial therapy for advanced breast cancer","volume":"11","author":"Sledge","year":"1992","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1023\/A:1008295427877_bb0080","first-page":"1146","article-title":"Epirubicin at four different dose levels in metastatic breast cancer","volume":"14","author":"Bastholt","year":"1996","journal-title":"A randomised trial. JCO"},{"key":"10.1023\/A:1008295427877_bb0085","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/BF00686176","article-title":"Epirubicin metabolism and pharmacokinetics after conventional and high-dose intravenous administration: A cross-over study","volume":"32","author":"Camaggi","year":"1993","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1023\/A:1008295427877_bb0090","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1023\/A:1008295427877_bb0095","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1200\/JCO.1984.2.5.472","article-title":"Measuring the quality of life of cancer patients: The Functional Living Index-Cancer: development and validation","volume":"2","author":"Schipper","year":"1984","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008295427877_bb0100","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0197-2456(81)90001-5","article-title":"Introduction to sample size determination and power analysis for clinical trials","volume":"2","author":"Lachin","year":"1981","journal-title":"Controlled Clin Trials"},{"key":"10.1023\/A:1008295427877_bb0105","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1200\/JCO.1993.11.7.1253","article-title":"Dose response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: A prospective randomised trial","volume":"11","author":"Focan","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008295427877_bb0110","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1093\/annonc\/6.suppl_1.S11","article-title":"High-dose chemotherapy of solid tumors","volume":"6","author":"Crown","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1008295427877_bb0115","series-title":"Proc Am Soc Oncol","first-page":"948","article-title":"Ultra-high-dose anthracycline combination therapy, with peripheral blood stem cell (PBSC), G-CSF and ADR-529 support","author":"Langleben","year":"1995"},{"issue":"4","key":"10.1023\/A:1008295427877_bb0120","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0959-8049(05)80145-5","article-title":"Decreased efficacy of cyclophosphamide, epirubicin and -fluorouracil in metastasic breast cancer when reducing treatment duration from 18 to 6 months","volume":"29A","author":"Ejlertsen","year":"1993","journal-title":"Eur J Cancer"},{"key":"10.1023\/A:1008295427877_bb0125","series-title":"Nimmo WS (ed): Clinical Measurement in Drug Evaluation. London: Wolfe Publishing Ltd","first-page":"131","article-title":"Anthracycline-induced cardio-toxicity and its relevance in cancer treatment","author":"Praga","year":"1991"},{"key":"10.1023\/A:1008295427877_bb0130","first-page":"83","article-title":"Epirubicin: Clinical toxicity during phase II program in endometrial and cervical cancer","volume":"13","author":"Calero","year":"1992","journal-title":"Eur J Gynaecol Oncol"},{"key":"10.1023\/A:1008295427877_bb0135","first-page":"1806","article-title":"Epirubicin cardio-toxicity","volume":"8","author":"Nielsen","year":"1990","journal-title":"A study of 135 patients with advanced breast cancer. J Clin Oncol"},{"key":"10.1023\/A:1008295427877_bb0140","first-page":"S20","article-title":"The role of anthracyclines in adjuvant chemotherapy of breast cancer: A critical appraisal","volume":"6","author":"Mourdisen","year":"1995","journal-title":"Fifth International Conference on Adjuvant Therapy of Primary Breast Cancer, St. Gallen. Anti-Cancer Drugs,"},{"key":"10.1023\/A:1008295427877_bb0145","series-title":"CMF in premenopausal women with node positive breast cancer. Proc Am Soc Oncol","first-page":"112","article-title":"A clinical trial of intensive CEF vs","author":"Levine","year":"1995"},{"key":"10.1023\/A:1008295427877_bb0150","first-page":"82","article-title":"A randomized trial of adjuvant chemotherapy with FEC 50 vs FEC 100 for node-positive operable breast cancer","volume":"15","author":"Bonneterre","year":"1996","journal-title":"Early report. Proc Am Soc Clin Oncol"},{"key":"10.1023\/A:1008295427877_bb0155","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.1992.10.1.102","article-title":"A phase II study of high-dose cyclophosphamide, thiothepa and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard dose therapy","volume":"10","author":"Antman","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008295427877_bb0160","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1200\/JCO.1986.4.5.646","article-title":"High-dose combination alkylant agents with autologous bone marrow support: A phase I trial","volume":"4","author":"Peters","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008295427877_bb0165","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1200\/JCO.1990.8.7.1207","article-title":"Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support","volume":"8","author":"Dunphy","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008295427877_bb0170","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/jnci\/83.13.920","article-title":"High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer","volume":"83","author":"Kennedy","year":"1991","journal-title":"J Natl Cancer Inst"},{"key":"10.1023\/A:1008295427877_bb0175","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1200\/JCO.1988.6.9.1368","article-title":"High dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer","volume":"6","author":"Peters","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008295427877_bb0180","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/oxfordjournals.annonc.a058903","article-title":"Paclitaxel and docetaxel: Not simply two of a kind","volume":"5","author":"Verweij","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1008295427877_bb0185","series-title":"Proc Am Soc Oncol","first-page":"258","article-title":"A phase I\u2013II study of taxotere in combination with adriamycin as first-line chemotherapy in patients with metastatic breast cancer","author":"Gruia","year":"1995"},{"key":"10.1023\/A:1008295427877_bb0190","series-title":"Proc Am Soc Oncol","first-page":"211","article-title":"Cardiac function in breast cancer patients given paclitaxel by 3 hours infusion and previous concomitant doxorubicin","author":"Munzone","year":"1995"},{"key":"10.1023\/A:1008295427877_bb0195","series-title":"Proc Am Soc Oncol","first-page":"256","article-title":"A phase I study of taxol (paclitaxel) and farmorubicin (epirubicin) in metastatic breast cancer: Preliminary results","author":"Spielmann","year":"1995"},{"key":"10.1023\/A:1008295427877_bb0200","first-page":"295","article-title":"Epirubicin at two dose levels with prednisone as treatment for advanced breast cancer","volume":"9","author":"Habeshaw","year":"1991","journal-title":"The results of a randomised trial. J Clin Oncol"},{"key":"10.1023\/A:1008295427877_bb0205","first-page":"126","article-title":"Evaluation of the epirubicin dose intensity in combination with a fixed dose of cyclophosphamide in metastatic breast cancer","volume":"5","author":"Marschner","year":"1994","journal-title":"Nineteenth Congress of the ESMO (Lisbon, Portugal). Ann Oncol"},{"issue":"2","key":"10.1023\/A:1008295427877_bb0210","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1200\/JCO.1991.9.2.305","article-title":"A prospective randomised trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients","volume":"9","year":"1991","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341948126X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375341948126X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/8\/2\/155\/19480594\/8-2-155.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T17:02:31Z","timestamp":1582218151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375341948126X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,2]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1997,2]]}},"alternative-id":["S092375341948126X"],"URL":"https:\/\/doi.org\/10.1023\/a:1008295427877","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[1997,2]]}}}